StemCell Therapy

In recent years, targeted cancer therapies have increased in use. These individualized treatments are based on the genetic makeup of a patient's disease.

Precision medicine in cancer is characterized by these personalized therapies, and it is tailored to address potential genetic changes in a patients tumor. By directly attacking the tumor, the researchers stress the impact this can have in protecting healthy cells that are also damaged during chemotherapy and radiotherapy, which can lead to severe toxicity in healthy tissues.

The researchers sought to provide an outline of emerging developments in targeted cancer therapy, particularly 2 areas of interest: immune-based therapy and enzyme-/small moleculesbased therapies. They included advancements in cancer targeted therapy, personalized medicine, and cancer combination therapies from research papers published from 2010 to June 2019.

Immune-Based Therapy

As the study authors discuss, immunotherapy-based strategies differ from both chemotherapy and radiotherapy-based treatments. Instead of directly attacking the growth of the cancer, the approach enhances the immune response to the cancer. Several notable innovations have increased the availability of this strategy, including immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens, and ligand targeted therapeutics.

ICIs have served as major advancements in oncology, with several already approved by the FDA. Although their impact in revolutionizing the treatment of cancer has been noted, there have also been reports they could cause serious harm to patients due to their toxicity, with some recipients reporting immune-related adverse events. The researchers highlight that further studies are warranted to gain a detailed understanding of tumors' mechanisms of resistance to checkpoint inhibitors treatment, in order to improve the therapy.

Enzyme-/Small MoleculesBased Therapies

In enzyme-/small moleculesbased therapies, the researchers cited innovations, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates, and antibody-directed enzyme prodrug therapy.

The PROTAC strategy has been expanded and utilized in the treatment of many diseases, including ER-positive breast cancer, and to target steroid hormone receptors for ubiquitination and degradation in breast and prostate cancers.

As the researchers note, the approach is inspired by a mechanism in which the cell degrades unwanted proteins and consists of a molecule with 2 independent moieties. Recently, PROTAC was used to degrade the anaplastic lymphoma kinase, which has been associated with several types of human cancer.

The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies, said the study authors.

Reference

Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine [published online February 25, 2020]. Biomed Pharmacother. doi: 10.1016/j.biopha.2020.110009.

View post:
Updates on Single, Combination Precision Medicine in Targeted Cancer Therapy - AJMC.com Managed Markets Network

ESCONDIDO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance edge computing, will host a webinar on how to bring supercomputing performance to data at the edge for AI applications with leaders from NVIDIA and Marvell.

The panel will be moderated by OSS chief sales and marketing officer, Jim Ison. He will be joined by Ying Yin Shih, director of product management at NVIDIA and Larry Wikelius, vice president, ecosystem and solutions at Marvell.

Topic: AI at the Edge: Bringing Supercomputing Performance to the DataThe webinar will discuss solving hard problems in defense, aerospace, autonomous vehicles, security, personalized medicine and more by leveraging massive NVIDIA enabled AI solutions designed for the unique size, power and rugged requirements of the edge.

A new computing paradigm is emerging that puts computing and storage resources for AI and HPC workflows not in the datacenter but on the edge near the data source. Applications continue to emerge for this new paradigm in diverse areas, including autonomous vehicles, precision medicine, battlefield command and control, industrial automation, and media and entertainment.

The common elements of these solutions are high data rate acquisition, high-speed and low-latency storage, and efficient, high-performance compute analyticsall configured to meet the unique environmental conditions of edge deployments.

This webinar will explain the challenges and solutions for meeting these requirements by describing real world use cases being developed and deployed today. OSS will present use cases of its edge-focused AI on the Fly products currently deployed in intelligence, surveillance and reconnaissance (ISR), genomic analysis, location-based entertainment, and autonomous driving.

NVIDIA and Marvell will describe their collaboration to support NVIDIA CUDA and CUDA-X software platform on the high performance, low power Arm architecture with Marvells ThunderX2 server processor. The combination provides a powerful tool in the expanding set of solutions for edge-focused AI infrastructure. The panel will discuss how CUDA for Arm provides an effective AI on the Fly building block for edge-oriented solutions where high performance, memory bandwidth and low power are essential.

Date: Wednesday, May 6 Time: 9:00 a.m. PDT

Register for this webinar today, click here.

About One Stop SystemsOne Stop Systems, Inc. (OSS) designs and manufactures innovative specialized high-performance computing modules and systems, including customized servers, compute accelerators, expansion systems, flash storage arrays and Ion Accelerator storage software. These products are used for deep learning, AI, defense, finance and entertainment applications, and empower scientists, engineers, creators and other professionals to push the boundaries of their industries.

OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for OEMs and government customers. The company enables AI on the Fly by bringing AI datacenter performance to the edge and on mobile platforms, and by addressing the entire AI workflow, from high speed data acquisition to deep learning, training and inference. OSS products are available directly or through global distributors. For more information, go to http://www.onestopsystems.com.

Forward-Looking StatementsOne Stop Systems cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the use of our products and applications in certain industries. The inclusion of forward-looking statements should not be regarded as a representation by One Stop Systems or its partners that any of our plans or expectations will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business, including, without limitation: risks associated with the fitness of One Stop Systems products and applications in certain industry sectors such as for autonomous vehicles, precision medicine, battlefield command and control, industrial automation, and media and entertainment; risks associated with the performance of our products that are combined into a third partys product, system, or application; and other risks described in our prior press releases and in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Trademarksin thispress releaseare theproperty of their respective owners.

Media Contact: Katie RiveraOne Stop Systems, Inc. Tel (760) 745-9883Email contact

Investor Relations:Ronald Both or Grant StudeCMATel (949) 432-7557 Email contact

Continued here:
OSS to Host AI at the Edge Webinar with Leaders from NVIDIA and Marvell - GlobeNewswire

As the coronavirus pandemic continues to spread around the globe, the world is facing an unprecedented crisis, carrying enormous financial and social costs unimaginable until recently. But these great difficulties also present opportunities for bold innovators to bypass bureaucracy and leapfrog their competitors, while rolling out revolutionary products at speed and scale. With the right leadership, innovative startups can use downturns to their advantage in the midst of economic crises. This can clearly be seen in Israels unique digital health innovation ecosystem.

The digital health sector is prospering in Israel. With more than 550 innovative companies, technology hubs, R&D centers, incubators, and multinational corporations in this space, the vibrant Israeli digital health ecosystem has more than doubled in size from 2011 to 2019. Now, the Startup Nation is leading the way with hundreds of scientists, innovators and investors racing to fight coronavirus. From faster diagnosis of COVID-19, to virtual homecare monitoring, to personalized medicine solutions disruptive technologies are being created and passed into service at extraordinary rates.

As historian Yuval Noah Harari recently stated, decisions that in normal times could take years of deliberation are passed in a matter of hours In normal times, governments, businesses and educational boards would never agree to conduct such experiments. But these arent normal times. Despite the risks these somewhat hurried experiments could pose to data privacy and potentially other civil liberties, many believe this may be a once-in-a-plaguetime opportunity for Israeli entrepreneurs to fast-track entry of novel technologies into the market.

Absence of epidemiological data

In order to roll out cutting-edge solutions and interventions, we vitally need one thing: easy collection and shared access to reliable global medical data and insights. Experts claim that Big Data - which analyzes large and complex datasets should be at the heart of the efforts to understand and forecast the impact that COVID-19 and other pandemics will have on all of us. But surprisingly, in todays digital world, such open flow of information barely exists in the healthcare sector.

Shutterstock

One of the most debated issues is the absence of epidemiological data on COVID-19 incidences in representative random samples of the general population. Just recently, the US Centers for Disease Control and Prevention announced new stunning evidence about the state of the virus: of 397 asymptomatic people tested at Bostons homeless shelter Pine Street Inn, 146 people, or 37%, tested positive for coronavirus. This is at a time when confirmed positive cases in Massachusetts amounted to roughly 0.4%. Similarly, researchers from Stanford University who recently tested 3,300 Californians in Santa Clara County for antibodies, found that the number of people who had been infected in the county was between 50 and 85 times higher than the confirmed case total.

Better predict the next outbreak

Equally important is the lack of clinical data on possible COVID-19 therapies. Three months into the outbreak, physicians are fighting an elusive enemy blindfolded, turning to experimental treatments without knowing where to look and which strategies are most likely to work.

The lack of both epidemiological and clinical data has become a huge concern for Dr. Dekel Taliaz, CEO of personalized medicine startup Taliaz, and President of Digital Health Technologies Israel, an umbrella body representing the digital health ecosystem in Israel. We would be in a totally different place if we had better access to up-to-date global medical insights, he says. Rather than decisionmakers relying on outdated or irrelevant statistics, they would be able to make flexible decisions based on real-life conditions.

This, of course, applies to future outbreaks of COVID-19 and other pandemics, as it gives the world data and tools to be able to better predict and pinpoint the next outbreak.

Real-time insights can outpace coronavirus

Imagine a world in which, based on artificial intelligence and predictive analytics, tailored sets of protocols with different levels of rigor could be implemented for every city, county and neighborhood. This is where startups like Israels Diagnostic Robotics come in. Together with Israels Ministry of Health, Diagnostic Robotics monitors, models and predicts infection trends over time, including daily geographic spread of exposed, suspected, confirmed and deteriorating patients. These dynamic COVID-19 heat maps support forecasts of community-level risk and expected strain on healthcare resources.

Other groundbreaking innovations include Datos Healths new remote management system for home-quarantined COVID-19 cases; and Binah.ais real-time remote vital signs monitoring app, which allows anyone to easily measure oxygen saturation, respiration rate, heart rate and heart rate variability just by looking into a smartphone camera. And this is just the tip of the iceberg.

The novel coronavirus is highly contagious and spreads at higher rates than initially estimated, Dr. Taliaz says. This means we need to support the development of digital tools with real-time insights that can outpace coronavirus. Taliaz has developed an artificial intelligence platform that analyzes clinical, demographic and genetic data to help doctors reduce trial and error by prescribing the right medication from the outset.

Decisionmakers need data to effectively conduct public health interventions

Considering the urgency and profound implications of the coronavirus pandemic, healthcare systems must act now, and some already do: the Israeli Ministry of Health has already opened access to its coronavirus database; similarly, South Korea has released a new website portal to support a global research collaboration on COVID-19.

While these are substantial strides forward, much information is still missing. Healthcare innovation is the backbone that will help us adapt, respond and overcome this pandemic. It is therefore critical to put in place an immediate global plan that makes the secure collection and sharing of anonymized, encrypted medical data a top priority. Now is the time to provide decisionmakers with the valuable data they need to transform existing rigid, static protocols into dynamic, data-driven public health interventions. If we choose global cooperation, we may not only protect our deeply interconnected world from coronavirus, but also prepare it for future pandemics.

Danielle Shapira of Maverick Ventures Israel contributed to this article. Maverick has invested in Diagnostic Robotics and Binah.ai.

Link:
Why Greater Access To Global Data Is Vital To The Fight Against COVID-19 And Future Pandemics - Forbes

The global healthcare industry is booming. As per recent research, it is expected to cross the $2 trillion mark this year, despite the sluggish economic outlook and global trade tensions. Human beings, in general, are living longer and healthier lives.

There is increased awareness about living organ donation. Robots are being used for gallbladder removals, hip replacements, and kidney transplants. Early diagnosis of skin cancers with minimum human error is a reality. Breast reconstructive surgeries have enabled breast cancer survivors to partake in rebuilding their glands.

All these jobs were unthinkable sixty years ago. Now is an exciting time for the global health care sector as it progresses along its journey for the future.

However, as the worldwide population of 7.7 billion is likely to reach 8.5 billion by 2030, meeting health needs could be a challenge. That is where significant advancements in machine learning (ML) can help identify infection risks, improve the accuracy of diagnostics, and design personalized treatment plans.

source: Deloitte Insights 2020 global health care outlook

In many cases, this technology can even enhance workflow efficiency in hospitals. The possibilities are endless and exciting, which brings us to an essential segment of the article:

Do you understand the concept of the LACE index?

Designed in Ontario in 2004, it identifies patients who are at risk of readmission or death within 30 days of being discharged from the hospital. The calculation is based on four factors length of stay of the patient in the hospital, acuity of admission, concurring diseases, and emergency room visits.

The LACE index is widely accepted as a quality of care barometer and is famously based on the theory of machine learning. Using the past health records of the patients, the concept helps to predict their future state of health. It enables medical professionals to allocate resources on time to reduce the mortality rate.

This technological advancement has started to lay the foundation for closer collaboration among industry stakeholders, affordable and less invasive surgery options, holistic therapies, and new care delivery models. Here are five examples of current and emerging ML innovations:

From the initial screening of drug compounds to calculating the success rates of a specific medicine based on physiological factors of the patients the Knight Cancer Institute in Oregon and Microsofts Project Hanover are currently applying this technology to personalize drug combinations to cure blood cancer.

Machine learning has also given birth to new methodologies such as precision medicine and next-generation sequencing that can ensure a drug has the right effect on the patients. For example, today, medical professionals can develop algorithms to understand disease processes and innovative design treatments for ailments like Type 2 diabetes.

Signing up volunteers for clinical trials is not easy. Many filters have to be applied to see who is fit for the study. With machine learning, collecting patient data such as past medical records, psychological behavior, family health history, and more is easy.

In addition, the technology is also used to monitor biological metrics of the volunteers and the possible harm of the clinical trials in the long-run. With such compelling data in hand, medical professionals can reduce the trial period, thereby reducing overall costs and increasing experiment effectiveness.

Every human body functions differently. Reactions to a food item, medicine, or season differ. That is why we have allergies. When such is the case, why is customizing the treatment options based on the patients medical data still such an odd thought?

Machine learning helps medical professionals determine the risk for each patient, depending on their symptoms, past medical records, and family history using micro-bio sensors. These minute gadgets monitor patient health and flag abnormalities without bias, thus enabling more sophisticated capabilities of measuring health.

Cisco reports that machine-to-machine connection in global healthcare is growing at a rate of 30% CAGR which is the highest compared to any other industry!

Machine learning is mainly used to mine and analyze patient data to find out patterns and carry out the diagnosis of so many medical conditions, one of them being skin cancer.

Over 5.4mn people in the US are diagnosed with this disease annually. Unfortunately, the diagnosis is a virtual and time-taking process. It relies on long clinical screenings, comprising a biopsy, dermoscopy, and histopathological examination.

But machine learning changes all that. Moleanalyzer, an Australia-based AI software application, calculates and compares the size, diameter, and structure of the moles. It enables the user to take pictures at predefined intervals to help differentiate between benign and malignant lesions on the skin.

The analysis lets oncologists confirm their skin cancer diagnosis using evaluation techniques combined with ML, and they can start the treatment faster than usual. Where experts could identify malignant skin tumors, only 86.6% correctly, Moleanalyzer successfully detected 95%.

Healthcare providers have to ideally submit reports to the government with necessary patient records that are treated at their hospitals.

Compliance policies are continually evolving, which is why it is even more critical to ensure the hospital sites to check if they are being compliant and functioning within the legal boundaries. With machine learning, it is easy to collect data from different sources, using different methods and formatting them correctly.

For data managers, comparing patient data from various clinics to ensure they are compliant could be an overwhelming process. Machine learning helps gather, compare, and maintain that data as per the standards laid down by the government, informs Dr. Nick Oberheiden, Founder and Attorney, Oberheiden P.C.

The healthcare industry is steadily transforming through innovative technologies like AI and ML. The latter will soon get integrated into practice as a diagnostic aid, particularly in primary care. It plays a crucial role in shaping a predictive, personalized, and preventive future, making treating people a breeze. What are your thoughts?

Image: Depositphotos.com

Read more from the original source:
How Machine Learning Is Redefining The Healthcare Industry - Small Business Trends

More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nations scientists need to be part of the global effort to address this pandemic.

Research Group Head, Amnion Cell Biology

There is no effective treatment to address the ongoing damage caused by for severe COVID-19 infections, said Associate Professor Rebecca Lim, Research Group Head of Amnion Cell Biology at Hudson Institute. Our team is investigating whether a cell therapy can be effective.

Amniotic epithelial cells (amnion cells) are from the amniotic sac which surrounds a baby during pregnancy. They have stem cell-like properties and can grow into many cell types. Most importantly, they have potent effects on inflammation and tissue damage.

A/Prof Lim and Professor Euan Wallace (Clinical Director, The Ritchie Centre) are developing a clinical trial to investigate whether these cells can help treat patients with COVID-19.

The team is working closely with intensivists at Monash Healths Intensive Care Unit to deliver a Phase 1b/2a clinical trial for COVID-19 positive patients requiring hospitalisation.

The goal of the trial is to determine if allogeneic amniotic epithelial cells are an effective therapy for severe COVID-19 complications. Specifically, the trial will test whether the cells can significantly reduce the cytokine storm associated with COVID-19 infection, encourage lung tissue to repair, and reduce the incidence of blood clotting and subsequent multi-organ complications including strokes, liver and kidney failure.

We have already shown that the allogeneic amniotic epithelial cells are safe and well-tolerated in extremely premature neonates and acutely unwell adults. So far, we have observed improvements in adult patients with liver disease and severe stroke. This points to the likely benefits for patients with COVID-19. These cells may also reduce the incidence and severity of the disease damage caused by blood clotting in tissues, A/Prof Lim said.

This project involves a partnership between Hudson Institute, Monash Health and Monash University-a team that leads the way in Victoria in cell therapy clinical trials targeting inflammation and regenerative medicine.

Victoria is perfectly placed to deliver a cell therapy treatment for COVID-19, A/Prof Lim said.

However, the trial requires funding.

The other trials using our cell-based therapies are in

Originally posted here:
Cell therapies trial planned for COVID-19 - Mirage News

As West Virginia starts to ease coronavirus-related restrictions, the states many residents with diabetes or pre-diabetes will have to navigate the transition with caution.

The Centers for Disease Control and Prevention says those at higher risk of severe illness from covid-19 include people 65 and older, people who live in a nursing home or long-term care facility, people with chronic lung disease or severe asthma, people who have severe heart conditions, people who are immunocompromised, people with severe obesity and people with diabetes.

Any of these chronic diseases, your immune system is compromised. When any disease and infection hits, your body and your bodys ability to fight that infection or disease its harder to do that, said Tracey Brown, chief executive of the American Diabetes Association.

West Virginia has many residents who fit each of those categories.

Diabetes is particularly prevalent.

The state Department of Health and Human Resources describes the rate of diabetes as an epidemic in West Virginia.

Fifteen percent of West Virginia adults has diabetes, according to DHHR. That ranked West Virginia at the top of the nation.

About 11 percent of West Virginia adults had pre-diabetes, according to DHHR.

The American Diabetes Association shows an even higher prevalence of those with pre-diabetes, 35 percent.

Serious complications from diabetes include heart disease, stroke, the necessity of amputation, blindness or death.

You can imagine that the correlation between diabetes and any underlying condition as it relates to covid-19, Brown said last week in an interview with MetroNews.

Everybody has the same risk factor for contracting covid-19 but when somebody with diabetes or an underlying condition contracts covid-19 there is a much higher likelihood of a poor outcome.

Brown and the American Diabetes Association sent a letter to Gov. Jim Justice asking for policies meant to help diabetics deal with the pandemic.

The letter expresses concern about the thousands of people who have experienced a job loss, which has also meant the loss of health insurance.

This is especially problematic for Americans living with diabetes who could now face significant out-of-pocket costs obtaining prescription medications and supplies, including insulin, and who are already among the most vulnerable to the pandemic due to their compromised immunity.

WV Justice 03262020 (Text)

The American Diabetes Association notes that during the past legislative session, officials placed a cap on insulin copayments at $100 for a 30-day supply.

During the pandemic response, the ADA recommends going a step farther to eliminate the copay, allowing it to resume when the crisis passes.

The last thing we want is for people to skip their medicines or ration their insulin, which puts them at greater risk of ending up in the hospital or ending up with bad health outcomes, Brown said. Thats one small thing that every state could do.

The ADA is also pushing for people who lose their jobs to be automatically enrolled in Medicaid and prohibiting their removal if they fail to pay or are late in paying premiums.

Not only do you have all of the things we should be doing, sheltering at home, social distancing, what you have on top of this now are businesses closing, furloughing people, laying people off, Brown said.

Many people have lost their health insurance. Their income has been greatly reduced. The medical expenses for a person living with diabetes is almost two and a half times higher than the people without diabetes.

Even before this, the medical costs of diabetes were enormous.

The American Diabetes Association estimates the costs of diabetes and pre-diabetes at $2.5 billion in West Virginia each year. That includes direct medical expenses as well as an estimate of indirect costs of lost productivity because of diabetes complications.

It is much better to keep people managing their diabetes that is so much better than going to the place of unmanaged where you hit complications and end up in the hospital. Thats a much worse decision and choice, Brown said.

This diabetes epidemic was truly an epidemic well before covid 19. What covid-19 is doing is shining a light on an epidemic that already should have been dealt with.

Read the original:
West Virginia's thousands of diabetics are among most susceptible to covid-19 - WV MetroNews - West Virginia MetroNews

A research team at Seoul National University College of Medicine has recently verified the safety and efficacy of metformin, a diabetes treatment, in diabetic nephropathy patients, and published it in Diabetics Care, an international journal.

The prevalence of chronic renal failure is increasing not only in Korea but also worldwide. According to the Korean Society of Nephrology reported that the estimated number of chronic renal failure patients in Korea totaled about 4.6 million in 2019, and the number of patients is increasing at an annual average rate of about 8.7 percent.

The leading cause of chronic renal failure is diabetic nephropathy caused by diabetes, and attention is now on the treatment of the disease as there are only a limited number of drugs available for treating diabetic nephropathy patients. Metformin has been the most commonly used diabetes drug over the past 60 years.

Although it is heap priced at 50 won (4 U.S. cents) per pill, the medicine is regaining interests as a substance that can prevent senile diseases such as cancer, heart disease, dementia, and blood sugar control, significantly extending patients life expectancy.

The American Diabetes Association and the Korean Society for Endocrinology recommend metformin as an initial treatment for diabetes. As the drug may increase the prevalence of fatal lactic acidosis in patients with chronic renal failure, however, the groups have banned the pill in patients with chronic renal failure of stage 3 or higher. Despite such limitations, there have been continued discussions suggesting that metformin treatment does not increase lactic acidosis compared to other diabetic drugs even in patients with chronic renal failure.

The SUU research team, led by Professor Lee Jeong-pyo, analyzed the dosing records of 10,426 diabetic renal failure patients at Seoul National University Hospital and Boramae Medical Center and found that metformin treatment was also effective in treating the disease and lowering the mortality rate in chronic stage 3B renal failure patients.

Also, the team discovered that metformin administration is safe in patients with chronic renal failure, as dosing with metformin did not increase the prevalence of lactic acidosis compared to other diabetes drugs.

Although this study may require additional prospective studies, we believe that the study has opened up the possibility for metformin, an inexpensive and effective drug for the development of cardiovascular diseases, in treating diabetic chronic renal failure patients, too, the team said.

corea022@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Read more here:
SNU proves safety, efficacy of metformin in diabetic nephropathy patients - Korea Biomedical Review

Online Diabetes Coaching Market research report growth rate, prices, market size, trading, and key vendors of the industrys information with forecast from 2020 to 2027. This research report also combines industry-wide statistically relevant quantitative data and relevant and insightful qualitative analysis. This report has published stating that the global Online Diabetes Coaching Market is anticipated to expand significantly at Million US$ in 2020 and is projected to reach Million US$ by 2027, at a CAGR of during the forecast period.

A complete study of the competitive landscape of the global Online Diabetes Coaching Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This study also provides an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Request Sample Copy of this Report @: https://www.qyreports.com/request-sample/?report-id=227438

Some of the key players operated in this report are:

Omada Health, Inc., Virta Health, Naturally Slim, Lark Health, Healthline Media.

Key questions answered in this report:

Factors that drive global opportunities have been surveyed in this research report to understand the current and prospective growth of the businesses. This study also offers an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Get Up To 40% Discount on this Premium Report @: https://www.qyreports.com/ask-for-discount/?report-id=227438

Regional Analysis:

Finally, all aspects of the global Online Diabetes Coaching Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

Major TOC points:

For More Information: https://www.qyreports.com/enquiry-before-buying/?report-id=227438

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About Us Qyreports:

We at, Qyreports, a leading market research report published accommodate more than 4,000 celebrated clients worldwide putting them at advantage in todays competitive world with our understanding of research. Our list of customers includes prestigious Chinese companies, multinational companies, SMEs and private equity firms whom we have helped grow and sustain with our fact-based research. Our business study covers a market size of over 30 industries offering unfailing insights into the analysis to reimagine your business. We specialize in forecasts needed for investing in a new project, to revolutionize your business, to become more customer centric and improve the quality of output.

Contact:

QYReports

Jones John

(Sales Manager)

204, Professional Centre,

7950 NW 53rd Street, Miami, Florida 33166

+1-510-560-6005

sales@qyreports.com

http://www.qyreports.com

Excerpt from:
Online Diabetes Coaching Market Expected to Reach at High Pace Projected to Witness Vigorous Expansion by 2020-2027 by Major innovators like Omada...

INDIANAPOLIS, April 30, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced free access to the mySugr Pro app to help the millions of Americans living with diabetes maintain their personalized daily diabetes routine during the COVID-19 crisis. This offer is especially beneficial as healthcare providers increasingly transition to remote patient visits.1,2

With the mySugr Pro app, users have access to valuable features to better manage their condition. They can create and share with their healthcare team detailed PDF reports of their aggregated diabetes data from Accu-Chek blood glucose meters, blood sugar levels, carbohydrate intake, stress levels, insulin dosages, medication, and estimated HbA1c. This efficient overview of information helps healthcare providers recognize patterns and individualize guidance. For people with diabetes, this helps prompt questions about blood sugar highs and lows for discussion with healthcare providers, enabling a satisfying experience during remote visits.3

For people with diabetes, good glucose control is important in avoiding or reducing the severity of infection. The risk of getting very sick from COVID-19 is likely to be lower if diabetes is well managed.4

"It is more important than ever for people with diabetes to feel supported in their self-management and connected to their healthcare team," said Matt Jewett, Senior Vice President and General Manager of Roche Diabetes Care, US. "Diabetes is well-suited to virtual care, and our goal is to facilitate highly productive interactions between healthcare providers and patients now and in the future."

With more than 2 million registered users worldwide, the mySugr app eases the complexity of the daily diabetes routine with data, motivation and detailed reports.

Visit accu-chek.com/mySugrPro to unlock the mySugr Pro features for free. This offer is valid until September 30, 2020.

For all further updates on our COVID-19 response, visitaccu-chek.com.

Rates of diabetes on the rise According to the International Diabetes Federation5 nearly half a billion (463 million) adults worldwide are currently living with diabetes; by 2045 this number will rise to 700 million. Controlling glycemic levels is critical in preventing long-term microvascular and macrovascular complications.6 As with many chronic diseases, the achievement of optimal therapeutic outcomes relies on both treatment persistence and treatment adherence.

References

[1] Virtual Diabetes Care during COVID-19: Practical Tips for the Diabetes Clinicianhttps://www.centerfordigitalhealthinnovation.org/posts/virtual-diabetes-care-during-covid19-practical-tips-for-the-diabetes-clinician. Accessed April 21, 2020 [2] The mySugr vouchercode can only be redeemed one time per user until September 30, 2020. The voucher code will enable mySugr pro version for 185 days. Void where prohibited by law.[3] Teresa L. Pearson, MS, RN, CDE, FAADE, Telehealth: Aiding Navigation Through the Perfect Storm of Diabetes Care in the Era of Healthcare Reform, Diabetes Spectrum2013 Nov;26(4):221-225.https://doi.org/10.2337/diaspect.26.4.221. .Section 7: Diabetes and Telehealth, Lines 7-10, Section 11: Nonface-to-face services conducted through live video conferencing or "store and forward" telecommunication services, Paragraph 3, Lines 7-13 https://spectrum.diabetesjournals.org/content/26/4/221%5B4%5D American Diabetes Association FAQ, Do people with diabetes have a higher chance of experiencing complications from COVID-19? Paragraph 2, Line 1 https://www.diabetes.org/covid-19-faq. Accessed April 21, 2020[5] IDF Facts & Figures, February 20, 2020: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed April 21, 2020[6] UK Prospective Diabetes Study Group: "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)." Lancet 352(9131): 837-853 (1998).

About mySugrFounded in 2012in Vienna, Austria, mySugr specializes in all-around care for people with diabetes. Its app and services combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and seamless integration with a growing number of medical devices to ease the daily burden of living with diabetes. The mySugr app has more than two million registered users and has received an average 4.6 star rating in theAppandPlay Store. The mySugr Logbook as well as the mySugr Bolus Calculator are both medical devices.

The mySugr App is available in 79 countries and 24 languages. mySugr joined the Roche Diabetes Care family in 2017. In addition to its headquarters in Vienna, the company has a second office in San Diego, California, and currently employs more than 175 people. For more information, please visitmysugr.com/en/for-media.

About Roche Diabetes CareRoche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.Being a global leader in integrated Personalized Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualise relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.

Since 2017, mySugr one of the most popular diabetes management apps is part of Roche Diabetes Care.

For more information, please visit http://www.rochediabetes.com, http://www.accu-chek.comand http://www.mysugr.com.

About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For more information please contact:- Amy Lynn (amy.lynn@roche.com)

View original content to download multimedia:http://www.prnewswire.com/news-releases/roche-offers-free-access-to-mysugr-pro-helping-people-with-diabetes-stay-connected-to-their-healthcare-team-during-covid-19-301049807.html

SOURCE Roche Diabetes Care

Original post:
Roche offers free access to mySugr Pro helping people with diabetes stay connected to their healthcare team during COVID-19 - P&T Community

Digital Diabetes Market research report growth rate, prices, market size, trading, and key vendors of the industrys information with forecast from 2020 to 2027. This research report also combines industry-wide statistically relevant quantitative data and relevant and insightful qualitative analysis. This report has published stating that the global Digital Diabetes Market is anticipated to expand significantly at Million US$ in 2020 and is projected to reach Million US$ by 2027, at a CAGR of during the forecast period.

A complete study of the competitive landscape of the global Digital Diabetes Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This study also provides an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Request Sample Copy of this Report @: https://www.qyreports.com/request-sample/?report-id=225993

Some of the key players operated in this report are:

Lifescan, Roche, Medtronic, Ascensia Diabetes Care, Tandem Diabetes Care, Dexcom, SocialDiabetes, One drop, H2 Inc., Dottli, Abbott Laboratories, Ypsomed holding AG, ARKRAY Inc, and Insulet Corporation.

Key questions answered in this report:

Factors that drive global opportunities have been surveyed in this research report to understand the current and prospective growth of the businesses. This study also offers an in-depth analysis of the global market with future estimates to identify current trends and investment trends for the forecast year 2020-2027.

Get Up To 40% Discount on this Premium Report @: https://www.qyreports.com/ask-for-discount/?report-id=225993

Regional Analysis:

Finally, all aspects of the global Digital Diabetes Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

Major TOC points:

For More Information: https://www.qyreports.com/enquiry-before-buying/?report-id=225993

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About Us Qyreports:

We at, Qyreports, a leading market research report published accommodate more than 4,000 celebrated clients worldwide putting them at advantage in todays competitive world with our understanding of research. Our list of customers includes prestigious Chinese companies, multinational companies, SMEs and private equity firms whom we have helped grow and sustain with our fact-based research. Our business study covers a market size of over 30 industries offering unfailing insights into the analysis to reimagine your business. We specialize in forecasts needed for investing in a new project, to revolutionize your business, to become more customer centric and improve the quality of output.

Contact:

QYReports

Jones John

(Sales Manager)

204, Professional Centre,

7950 NW 53rd Street, Miami, Florida 33166

+1-510-560-6005

sales@qyreports.com

http://www.qyreports.com

Digital medicines are designed to communicate with mobile and / or web-based applications where a patient has been taking a certain dose of a drug at a specific time. Digital medicines are used in a variety of conditions in commercial

See more here:
Exclusive Demand for Digital Diabetes Market Projected to Witness Vigorous Expansion by 2020-2027 by Major innovators like Lifescan, Roche, Medtronic,...

R. Kellys attorneys are desperately trying to get him out of jail. Now, they are claiming Kelly is a diabetic and at high risk for complications if he catches the coronavirus behind bars.

Billboard reported yesterday that Kelly is likely diabetic, testing just 1/10 of one point below diabetic. Kellys high blood pressure, cholesterol, and weight issues put him in the very top of the high-risk category to catch coronavirus.

His attorney, Steven Greenberg, is demanding for the third time that his client is released from prison. Eleven days prior to Greenbergs appeal, the judge presiding over the case denied Kellys second request to be released from jail while awaiting trial. Greenberg claims that the Bureau of Prisons did not release Kellys diabetic results for almost a month and that no medical attention has been given to Kelly to help with his pre-existing conditions.

However, U.S. AttorneyRichard P. Donoghueargued this idea. He stated that R. Kelly is a flight risk and a danger to the community. In a memo to the court, Donoghue reminded the court of the charges against Kelly in Chicago. They include conspiracy to obstruct justice and a conspiracy to receive child pornography, including during the years he was on bail awaiting trial. Donoghue argues that Kelly might have committed at least five serious crimes while out on bail.

Prosecutors also stated that it was disingenuous for Kelly to say he cannot go anywhere when he received $200,000 in royalties in the first quarter of 2020 and still has a significant network of individuals to assist him on the outside.

While the government recognizes the seriousness of COVID-19 and the increased risk to certain federal prisoners, a generalized risk alone does not justify releasing the entire BOP populations, much less a prisoner being held for racketeering charges involving crimes against specified victims and with a history of obstructing justice and violating his bail conditions by committing serious crimes, Donoghue explained in previous motions to the court.

Greenberg, however, still believes in his clients innocence, saying that R. Kelly will wear a GPS tracker if released and adhere to restricted internet and cell phone use.

Read more:
R. Kelly's Attorneys Say He Is Diabetic and Should be Released From Jail - The Source

You may not think of plants as needing life-saving medicine, but that's sometimes the case when bugs and disease strike. Now, scientists have developed a super-accurate, highly delicate way of delivering drugs, and right where plants need them.

At the moment, plants can be sprayed with pesticides, which doesn't really penetrate to the roots, or they can be treated with large needles that aren't particularly precise, and tend to cause damage to the plants.

The new method makes use of microneedles or what the researchers are calling 'phytoinjectors', sitting on top of a silk-based biomaterial patch, which are able to hit a plant's circulatory system directly. Pesticides, in contrast, might travel between the root system and the leaves.

(Cao et al., Advanced Science, 2020)

As well as delivering medicine or nutrients to different parts of the plant, the new mechanism could also be used to take samples of a plant, which are then transferred to a lab for analysis, or even to edit DNA (something the team has successfully tried).

"We wanted to solve the technical problem of how you can have a precise access to the plant vasculature," says mechanical engineer Yunteng Caofrom MIT.

"You can think about delivering micronutrients, or you can think about delivering genes, to change the gene expression of the plant or to basically engineer a plant."

The motivation for the project came from the spread of the citrus greening disease across the US and other parts of the world, which threatens to flatten an industry worth $9 billion if a solution isn't found. Olives and bananas are other fruits under particular threat from disease across the world right now.

Previous work looking at the use of microneedles to deliver human vaccines was used as a starting point, with silk kept as the basis of the material holding the microneedles.

Silk is strong, doesn't cause a reaction in plants, and can be made degradable enough to get out of the way once the drugs have been delivered.

However, a lot also had to change compared to microneedles used on humans: plants have far less water available than the human body does, so the design had to be adapted.

The team of scientists was able to boost the silk's hydrophilicity (water-attracting capabilities), and come up with a new material more suited for plants.

"We found that adaptations of a material designed for drug delivery in humans to plants was not straightforward, due to differences not only in tissue vasculature, but also in fluid composition," says biologist Eugene Lim.

Tests of the material and its microneedled payload on tomato and tobacco plants showed that it could be successful as a drug delivery system. Fluorescent molecules were used to track the progress of the injection all the way from the roots to the leaves.

The system should adapt to other plants fairly easily, the researchers say, though scaling it up is going to prove more challenging. The work should prove useful for future projects though, both in delivering life-saving drugs to save plants from disease, and in engineering them to avoid disease in the first place.

"For the future, our research interests will go beyond antibiotic delivery to genetic engineering and point-of-care diagnostics based on metabolite sampling," says environmental engineer Benedetto Marelli.

The research has been published in Advanced Science.

Visit link:
Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert

WITH food security trending across social media sites, its important to take note of the blue-sky research being carried out in Australia to future-proof our food.

While panic buying and poor logistics have caused the majority of food shortages on Australian supermarket shelves, long-term climate trends and the commercial realities of needing to 'grow more with less' have been driving researchers toward altering the way plants grow at a fundamental level.

Despite the long-winded name, the Australian National University's (ANU) Australian Research Council Centre of Excellence for Transitional Photosynthesis has a rather straightforward mission - research the ways photosynthesis can be altered to increase yield in food crops.

Centre director and ANU professor Robert Furbank said photosynthesis, the process green plants use to convert sunlight into chemical energy, could give farmers the tools to increase crop production while battling with changes to the climate.

"Australian plant scientists are punching above their weight by participating in global, interdisciplinary efforts to find ways to increase crop production," professor Furbank said.

"We essentially need to double the production of major cereals before 2050 to secure food availability for the rapidly growing world population."

Initial outcomes from the research were recently published in the Journal of Experimental Botany.

Co-editor and ANU researcher professor John Evans said the publications showed how improving photosynthesis could benefit food production.

"We are working on improving photosynthesis on different fronts, from finding crop varieties that need less water, to tweaking parts of the process in order to capture more carbon dioxide and sunlight," professor Evans said.

"We know that there is a delay of at least a decade to get these solutions to the breeders and farmers, so we need to start developing new opportunities now before we run out of options."

Professor Evans said the research covers everything from genetic engineering to synthetic biology, working across crops such as wheat, rice and sorghum.

While the pay-off from this sort of 'blue-sky' research can be decades away, professor Furbank said it was important the research was conducted now.

"It is similar to finding a virus vaccine to solve a pandemic, it doesn't happen overnight.

"We know that Australia's agriculture is going to be one area of the world that is most affected by climate extremes, so we are preparing to have a toolbox of plant innovations ready to ensure global food security in a decade or so."

Professor Furbank said this was why long-term proactive funding for blue-sky research was needed.

Read more:
Blue-sky thinking for food production - Farm Weekly

The statement by the pro-GMO expert in an article published in the Ethiopia Observer: [GMOs] in principle, [] could allow increased yield and lower production costs, which translates to increased farm income, lacks moral correctness and it is built more on theory than reality.

The author has every right to promote Genetically Modified Organisms (GMOs) but his article is one-sided, selective in its use of studies, and full of factual errors. The author who has a manifestly unbridled enthusiasm for GMOs makes some overconfident claims, starting from his opening line which says, genetically modified (GM) traits can be valuable and the discussion around them should be based on facts and in a case-by-case approach. However, he did not provide enough case-by-case examples of these traits that could be relevant to solve the problems of smallholder farmers in Ethiopia. After all, any technological intervention must be based on the needs and realities of those smallholder farmers who are the main producers of food and raw material for industrial production in Ethiopia. For instance, we have yet to see GM traits that could be effective to mitigate the devastating wheat rust, withstand extreme drought and frost, and provide a higher yield than existing crop varieties. There are numerous writings that wax lyrical about the virtues of GMOs, many of them written by paid advocates. But independent assessments on the nature and performance of GM crops in comparison with conventionally improved varieties are rare. Even if we must advocate for GMOs, it must be in consideration of the countrys interest than that of the multinationals, whose sole motive is nothing more than profit. We must also communicate facts that are relevant for smallholder farming in Ethiopia instead of stories from commercial farming in the U.S. or other industrialized countries. If the GM traits must be there, it must be with the aim to solve farmers problems.

Indeed, GMOs should not be confused with the use of biotechnology as a science. There are biotechnology tools such as marker-assisted selection that are cheaper and can be helpful in countries like Ethiopia to develop new varieties in a short period of time for use. These kinds of technologies are less risky and easy to integrate with conventional breeding in pro-poor public research institutions.

In the first paragraph, the author wrote, the genome of organisms can be altered to contain [a] genetic variants so that the GMO can express a desired trait, which could, for instance, be drought-tolerance. He adds, in principle, this could allow increased yield and lower production costs, which translates to increased farm income. The truth of the matter is, we have not yet seen super varieties or GM cultivars that have led to a huge surge in yields and tolerate moisture stress. High yield already exists in conventionally breed improved varieties. Most GMOs are created by inserting genes (e.g. from bacteria) into these high yielding varieties to produce toxins that kill insects or to become herbicide tolerant. Thus, two types of GM crops dominate todays market.

Insect-resistant GM crops these types of GM crops are developed by introducing a gene fromBacillus thuringiensis(Bt), a soil bacterium. Such GM plants or Bt-plants were created to produce toxins that kill insect pests. The advantage is that we avoid spraying synthetic chemicals to control insect-pest by growing Bt-crops. This is useful for the environment and the economy of the producer. But things get murkier when the insect evolves through time and develop resistance to Bt toxin produced by the plants. Insect resistance by GM crops breaks as much as those varieties developed through conventional breeding. Studies have already shown this problem. This would force farmers to go back to using chemicals to control the pest, making the cost of production higher as farmers would be obliged to buy expensive GM seeds as well as associated insecticidal chemicals. It also means farmers would be required to spray more chemicals, which is bad for the environment. Another problem with GM crops is that they do not have certain features compared to their counterpart conventional varieties while they maintain insect resistance. For instance, the Bt-cotton failed in Burkina Faso because the fiber quality of cotton was below standard, and farmers were forced to sell at a low price. Generally, GM crops have not demonstrated superior performance compared to conventional varieties in this regard but one thing that we could speak with certitude is they increase production costs. This is because all GMOs are patented, which makes the seeds and associated agrochemical inputs more expensive. Thus, the patent on such GM crops is an incentive for the multinationals to accumulate wealth at the expense of poor farmers.

Herbicide-tolerant GM crops these types of GM crops are modified to tolerate huge doses of chemical herbicide e.g. Roundup Ready GM soybeans. Roundup kills non-modified normal soya plants and weeds. In other words, normal soya plants and all other unwanted plants in the field (weeds) die except those GM soya plants when we spray them with Roundup. Indeed, this makes weed control easier or manageable when we have a huge soya field which otherwise is difficult to control weeds by manual weeding. This can be beneficial for large scale farmers in developed countries where labor is expensive. The problem with this type of GM crop is the emergence of superweeds as observed in recent years. These are tolerant weeds that are no longer killed by Roundup and growers must spray more of it to control weed infestation. This means it exacerbates the environmental hazard. It increases water, soil, and air pollution, which can have a devastating effect on human and ecosystem health. Still, the winners are companies who earn from the sale of a patented chemical (roundup) and GM soya seeds.

Companies are now grabbing plant genetic resources by incorporating genes from traditional plant varieties and wild relatives into GM crops through patenting.

The author correctly points out that altering the genomes of plants and animals did not begin with the emergence of genetic engineering (GE) and genetic modification in recent decades. In fact, people have been altering the genomes of plants and animals for thousands of years starting from domestication through to traditional selection and modern-day breeding, he wrote. This is why many observers find patenting plants and animals outrageous because the diversity of crops that we have today is the result of thousands of years of selection and management by farmers. Companies are now grabbing plant genetic resources by incorporating genes from traditional plant varieties and crop wild relatives into GM crops through patenting It must be underlined that companies are not inventing genes, but they are simply isolating them from farmers varieties or genetic resources in the public domain. They would go on introducing these genes to a new one to claim a patent, which gives them complete monopoly of the genes. The example of introducing a gene that confers resistance to Xanthomonas from sweet pepper to banana shows this technological practice. The same thing is being tried on Enset. This becomes unfair when the technology is monopolized by a handful of multinational companies through patents.

In my view, it is insincere to promote GMOs in a country that has weak or insufficient biosafety regulatory frameworks such as biotechnology and/or biosafety policy, laws, regulations and guidelines, administrative systems, decision-making systems and mechanisms for public engagement.

In addition to hiding these socio-economic harms from use of GMOs, the author intentionally avoids distinguishing genetic engineering from conventional breeding including the selection of better plant varieties by farmers. Genetic engineering (that involves the transfer of genes from unrelated organism to another such as between bacteria and plants to create transgenic organisms), and Genetic modification (that involves modifying the DNA of an organism by removing, replacing some genes or inserting genes from other plants of the same species) is different from farmers selection practices (conscious or unconscious). The later resulted in an enormous diversity of crops and animals we have today. This is a common communication practice by pro-GMO experts to ignore the socio-economic and ecological risks of GMOs. In my view, it is insincere to promote GMOs in a country that has weak or insufficient biosafety regulatory frameworks such as biotechnology and/or biosafety policy, laws, regulations and guidelines, administrative systems, decision-making systems and mechanisms for public engagement. While the authors doubt about Ethiopias eco-leadership is forgivable, the fact he stressed regarding earlier cultivation of GMOs in other African countries is undeniable.

I leave it to the author to learn about Ethiopias Pan-African environmental initiative by reading Dr. Melaku Woreds work and that of Dr. Tewolde Berhan Gebre Egziabher. Earlier cultivation of GMOs in other African countries is true, as the author points out. But he avoids mentioning that the use of GMOs has been restricted to few crops and countries on the continent. The U.S. and its agri-conglomerates pushed for commercial cultivation of GM crops in South Africa in the late 1990s following the countrys transition to democracy from apartheid. It is no accident, that they are trying to push for the same market opportunity in Ethiopia today. They see a similar moment in the countrys history a transition from authoritarian rule to democracy. In the last 20 years, big commercial farmers in South Africa have been growing GMOs. Egypt and Sudan have allowed GM crop cultivation, especially Bt-Cotton. Burkina Faso tried to do the same, but it largely failed. Overall, GMOs have not expanded to many African countries as hoped by the U.S and its companies in the 1990s and later years. Ethiopia, Rwanda, and Uganda seem to be the new target countries now. Uganda has allowed trials for the genetically modified banana in the last few years. Rwanda is considering opening up to genetically modified potato. GMOs have also made their way to the African Union in the form of policy through the development of the African Seed and Biotechnology Programme in 2008. But the program focuses on overall seed system development and states that GMOs can be one alternative, but it should be managed safely. I would also like to remind the author that this program was developed based on the African Model law that Ethiopia drafted in 2000, before its relaxation due to pressure from western donors and new philanthropists such as Bill and Melinda Gates Foundation. It is understandable for the author to say that GM can be a valuable tool but is no cure-all when he argues using a study done by people from Agri-food group and a study that uses data from the internet (a literature review of studies mostly done/financed by Monsanto and other companies) instead of filed level environmental and socio-economic impacts of GMOs to make conclusions. What we have been lacking is an independent study of GMOs that has no affiliation to pro- and ant-GMO movements. So, all these praises dont support the authors claims.

The author also tells that for countries with foreign currency bottlenecks like Ethiopia, reduced use of inputs such as pesticide, insecticide, and herbicide could translate to substantial foreign currency savings. Unfortunately, this is premised on flawed reasoning. Ethiopia could earn more foreign currency from exporting its organic products. Buying a technology that others benefit from will not solve its currency problem. Rather Ethiopias export will be questioned after the adoption of GMOs especially in Europe where GMOs are not welcomed both by consumers and their strict regulatory framework.

Another argument by the author is the labor-saving benefits of insect-resistant and herbicide-tolerant maize varieties. This is beside the point. It is strange to argue in this manner in a country where millions of young people are not in employment. The country might have many other problems but not labor. The author also said, GM also offers an adaptive capacity against an increasingly unpredictable future. What is proof of this? Of course, there is not. The author has simply overstretched himself. In my view, there is no risk that vulnerable smallholder farmers can bear, and Pro-GMO experts need to be honest and build public trust in Ethiopia

Image: Cotton farmers near Arba Minch, southern Ethiopia, photo Ecotextile.

This article is published under aCreative Commons Attribution-NonCommercial 4.0 International licence. Please cite Ethiopia Observer prominently and link clearly to the original article if you republish. If you have any queries, please contact us at ethiopiaobserver@protonmail.com. Check individual images for licensing details.

Continue reading here:
We need more honesty in GMO discussions - Ethiopia Observer

Having served over half her sentence, Lulu was a candidate for medical parole based on her age and health even before the coronavirus crisis. Her medical history included chronic obstructive pulmonary disease, hepatitis C, seizure disorder, and stage stage-five chronic kidney disease. She also had a heart attack and open-heart surgery in January. Release for Lulu and others in similar situations became a more urgent public health issue during the pandemic. Since early March, academic experts, medical and legal professionals, and advocates have been requesting broad release for incarcerated New Yorkersespecially the elderly, the pregnant, and those with underlying health conditions.

In jails and prisons, social distancing is impossible, and there are minimal sanitary supplies and limited medical capacity. The Release Aging People from Prison (RAPP) Campaign had called for the 9,550 people age 50 and older in state prisons be freed. As of April 30, Cuomo had released 116 older people from prisonor approximately 1 percent of the over-50 population. (He also ordered the release of up to 1,100 people in local jails on low-level parole violations.) Were Cuomo to allow the most vulnerable to go home, Donna Robinson, RAPPs Western New York regional organizer, told me, so many lives would not be lostnot only of people who are incarcerated, but the guards, the vendors, the volunteers.

As of May 1, 1,074 staff members and 375 incarcerated people at New York State prisons are confirmed positive for Covid-19; ten incarcerated people and two staff members have died. On March 30, a top doctor at New Yorks Rikers Island Jail tweeted that, in 12 days, one Covid-19 case had exploded into 200, that the virus was spreading rapidly, and that it was unlikely that the jail could stem the growth. By April 30, there were 376 cases, an infection rate of nearly 10 percent, compared to the civilian rate of 1.5 percent in the rest of the state. All numbers only reflect those who have been given tests, which are notoriously in short supply. When the Bureau of Prisons, which controls federal facilities, tested 2,700 incarcerated people for Covid-19, 71 percent of the tests came back positive.

All visitation to Bedford Hills was canceled on March 16. Incarcerated women, civilian workers, guards, and their families fell ill. Lulu wrote to Melissa on March 20, cheerful as usual, grateful for her care package of popcorn and Honey Buns. Hey Sis, How are you doing? Is the sun out up north? I got the stuff you sent me Thank you very much for all that you did Love you both and tell the kids I said hello and to continuously wash their hands and face. Love LuLu. As the virus circulated, she grew anxious. On March 28, she asked Melissa to contact people in higher places and let them know. With her underlying health issues, she added, I cannot afford to get this virus. It may kill me. Please help.

See more here:
Death of a Survivor - The New Republic

This report also researches and evaluates the impact of Covid-19 outbreak on the Animal Stem Cell Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Animal Stem Cell Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Latest Market Research Report onAnimal Stem Cell Therapy Market size | Industry Segment by Applications (Veterinary Hospitals and Research Organizations), by Type (Dogs, Horses and Others), Regional Outlook, Market Demand, Latest Trends, Animal Stem Cell Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report also assesses driving forces of Animal Stem Cell Therapy market and changing dynamics which have been examined as growth-boosting factor. Also, the Animal Stem Cell Therapy study sheds light on limitations and restraints that could probably become obstruction while the Animal Stem Cell Therapy industry is proceeding to achieve substantial revenue. The report also aids readers to gain in-depth knowledge of a Animal Stem Cell Therapy market environment that comprises terms such as entry barriers, and trading policies as well as regulatory, political, financial and social concerns that may also hamper Animal Stem Cell Therapy market growth momentum.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/1189

It also facilitates clients with the acumen to gain competitive advantages in the Animal Stem Cell Therapy market and the strengths and weaknesses of their strong opponents. The Animal Stem Cell Therapy report emphasizes their strategic movements including brand expansions, public relations activities and product releases. The report highlights ideas, objectives, core business values, and niche markets of leading contributors operating in the worldwide Animal Stem Cell Therapy industry.

Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies are the main audience for Animal Stem Cell Therapy market involved in this report.

Report Scope:

Animal Stem Cell Therapy market competition by top Manufacturers:

Animal Stem Cell Therapy Market Outlook by Applications:

Animal Stem Cell Therapy Market Statistics by Types:

The study includes the profiles of key players in the Animal Stem Cell Therapy market with a significant global and/or regional presence. The study on the global Animal Stem Cell Therapy market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

With the clear insight this report also helps in understanding Animal Stem Cell Therapy market dynamics, structure by analyzing the Animal Stem Cell Therapy market segments, and project the Animal Stem Cell Therapy market size. Actual market sizes and forecasts have been provided for all the above-mentioned segments.

The foremost points are labelled in detail which are covered in this Animal Stem Cell Therapy Market Report:

The Animal Stem Cell Therapy Analysis report offers an entire substantial study of the Animal Stem Cell Therapy market, key tactics followed by leading Animal Stem Cell Therapy industry Players and impending segments. The previous and current Animal Stem Cell Therapy industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Animal Stem Cell Therapy market analysis report.

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/1189

More:
Animal Stem Cell Therapy Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

- Company's goal to initiate clinical trial in patients in 2020

- Innovative therapy candidate uses next generation mesenchymal stem cells (MSCs) derived from a master cell bank of induced pluripotent stem cells (iPSCs)

CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

The cells, called NoveCite Cells or NC-MSCs, are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. NC-MSCs are mesenchymal stem cells derived from a single donor's fibroblasts that have been dedifferentiated into an induced pluripotent stem cell (iPSC) master cell bank, thereby avoiding the need to source additional donor cells. The iPSCs are then further differentiated into a mesenchymal stem cell (MSC) therapy. Citius and Novellus plan to develop NC-MSCs for the treatment of ARDS, and last month the companies signed an exclusive option agreement.

The Company plans a multi-center randomized placebo-controlled dose-finding study followed by an expansion phase to assess the safety, tolerability, and efficacy of NC-MSCs in patients with moderate to severe ARDS due to COVID-19. The proposed trial, a Phase 1b/2 clinical trial, is titled "A Randomized Placebo-Controlled Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19)," or "MARCO". The primary objectives of this study are to evaluate the safety and efficacy of NoveCite cells as a treatment for subjects with moderate-to-severe ARDS due to COVID-19 and to identify therapeutic doses.

"MSCs have an established track-record of clinical safety, and have shown promise in the treatment of inflammatory lung disease," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus, Inc. "Our research has shown that the NoveCite cells, being derived from mRNA-reprogrammed iPSCs, secrete higher levels of immunomodulatory proteins than donor-derived MSCs, and have unique manufacturing advantages."

"We believe we have the key elements in place from a clinical design and manufacturing point of view to evaluate this novel cell therapy approach to deal with the current pandemic," said Myron Holubiak, Chief Executive Officer of Citius. "ARDS is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80% of the deaths in ventilated patients. There is no proven or FDA-approved treatment for it, other than oxygen therapy, including use of mechanical ventilation, and fluid management. Literature from previous investigational studies with MSCs in the treatment of lung injuries support the idea that MSCs could prove effective in treating COVID-19-related ARDS. We look forward to our FDA discussions and are excited to be at the cusp of what could be a novel and effective therapy for ARDS."

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Story continues

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 will benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Inc.Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement with Novellus within the option period; our need for substantial additional funds; the ability to access the FDA's CTAP program for the MARCO trial; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks associated with conducting trials for our product candidates, including those expected to be required for any treatment for ARDS and our Phase III trial for Mino-Lok; risks relating to the results of research and development activities; risks associated with developing our product candidates, including any licensed from Novellus, including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; uncertainties relating to preclinical and clinical testing; the early stage of products under development; risks related to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-announces-pre-ind-submission-to-fda-under-the-coronavirus-treatment-acceleration-program-for-a-novel-stem-cell-therapy-for-acute-respiratory-distress-syndrome-ards-in-covid-19-301047150.html

SOURCE Citius Pharmaceuticals, Inc.

Read this article:
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic, it is initiating staff layoffs, anticipated to affect 12 employees, primarily research and development personnel. The layoffs are expected to be completed on or around May 1, 2020. AgeX expects to pay approximately $105,000 in accrued payroll and unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which are expected to be settled in cash.

AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology. Since the launch of its licensing and collaboration strategy in January 2020, AgeX delivered a research collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte, and entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem at a California state university. AgeXs budgetary and personnel adjustments will result in the deferral of in-house work on the development of AgeX therapy product candidates, including AGEX-VASC1 and AGEX-BAT1, and its induced tissue regeneration (iTR) technology, and may also lead to outsourcing of some of that work, until further funding can be obtained to rebuild a research and development staff for one or more of those programs. Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

The rest is here:
AgeX Therapeutics Announces Reduction in Projected Cash Expenditures - Business Wire

In 2018, the market size of Canine Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Canine Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Canine Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Canine Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

This study presents the Canine Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Canine Stem Cell Therapy history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Canine Stem Cell Therapy market, the following companies are covered:

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Canine Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Canine Stem Cell Therapy, with price, sales, revenue and global market share of Canine Stem Cell Therapy in 2017 and 2018.

Chapter 3, the Canine Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Canine Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Canine Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Canine Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the original here:
Global Canine Stem Cell Therapy Market's Growth Trajectory Disrupted by COVID-19 Pandemic; Growth to be Restored Post Crisis Science Market Reports -...

Allosource

Stem Cell Therapy Market Competitive Landscape

In the last chapter, the analysts have studied the competitive landscape present in the Stem Cell Therapy market. The chapter also includes comments and recommendations by market experts to help the readers make the right decisions for their businesses for the forecast period. The chapter on competitive landscape presents a list of achievements made by these companies so far, mergers and acquisitions, and product innovations.

Stem Cell Therapy Market Segmentation

The extensive report on the Stem Cell Therapy market includes an executive summary that gives a brief description of the overall market, its drivers, restraints, leading segments, and competitive landscape. Each part of the executive is separately explained in the research report through dedicated chapters. The chapters are complete with precise calculations through charts and graphs.

The publication also includes individual chapters on various segments present in the market and the relevant sub-segments. Analysts have provided historical revenues and estimated revenues for all of the segments. Sales of products and the evolution of end-users have also been studied in the research report. The chapter on geographical analysis assesses the regional markets. It takes a granular view of the changing socio-political conditions, weather changes, and annual budgets of nations to determine their impact on the overall market.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=NYH&utm_medium=001

Report Objectives

Analyzing the size of the Stem Cell Therapy market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the Stem Cell Therapy market.

Exploring the key dynamics of the Stem Cell Therapy market.

Highlighting important trends of the Stem Cell Therapy market in terms of production, revenue, and sales.

Deeply profiling top players of the Stem Cell Therapy market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the Stem Cell Therapy market.

Forecasting the market size and share of all segments, regions, and the global market.

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=NYH&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Stem Cell Therapy Market Growth Opportunities, Key Companies, Outlook, Drivers and Forecast to 2026 - New York Headlines USA